Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
| ▸ | PPID | Q08752 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780144 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL28186906 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| Hydrochloric Acid SCHEMBL3366422 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| Hydrochloric Acid SCHEMBL7323482 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL14776455 | 0.89 | PDCD1 (0.48) | MMP8MEN1KMT2APDCD1CD274 | |
| SCHEMBL14776768 | 0.88 | MEN1 (0.49) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL10519227 | 0.88 | PPID (0.43) | SMN1; SMN2PPIDMEN1KMT2APDCD1 | |
| SCHEMBL1839763 | 0.88 | ATM (0.55) | MAPTMEN1KMT2AATM | |
| SCHEMBL1526134 | 0.88 | ATM (0.55) | MAPTMEN1KMT2AATM | |
| SCHEMBL7856109 | 0.88 | ATM (0.55) | MAPTMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3015488-B1 | PRODUCTION METHOD FOR POLYAMINO ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-10336864-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9815938-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-3015488-A1 | PRODUCTION METHOD FOR POLYAMINO ACID | Takeda Pharmaceutical Company Limited (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-25 | — | — | US | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0724601-A4 | S 3N CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORP (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5684137-A | TECHNETIUM AND RHENIUM LABELS FOR LIGANDS AND PROTEINS | NEORX CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0724601-A1 | S 3N CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORPORATION (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995005398-A1 | S3N CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORPORATION (US) | 1995-02-23 | — | — | WO | disclosed |
| US-5252721-A | S3 N chelating compounds | NEORX CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
| US-4827016-A | TREATMENT OF SUNBURN | MORGAN LEE R (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0300100-A1 | Method and compounds for reducing dermal inflammations | Morgan, Lee Roy (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | SMN1; SMN2 665/4885MMP8 1150/4885PPID 2641/4885 |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | SMN1; SMN2 4567/4885MMP8 4693/4885PPID 2096/4885 |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | TERT, C5, DERA | SMN1; SMN2 1018/4885MMP8 889/4885PPID 1912/4885 |
| US-10336864-B2 | Production method for poly(amino acid) | PGA5, ENPEP, PARG | SMN1; SMN2 4567/4885MMP8 4693/4885PPID 2096/4885 |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | SMN1; SMN2 4567/4885MMP8 4693/4885PPID 2096/4885 |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | TYMS, TERT, TYMP | SMN1; SMN2 2656/4885MMP8 1968/4885PPID 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.